Jackson Center, PA, October 1, 2020 – Halberd Corporation (OTC-PINK: “HALB“) announced they have obtained world-wide license to a provisional patent application covering a nasal spray to be used as a prevention measure against coronavirus.  The provisional patent, “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans,” was filed recently with the U.S. Patent and Trademark Office by its inventor, Mitchell S. Felder, MD.

The nasal spray is intended to be used as a prophylactic against contracting Covid-19 specifically, and coronaviruses in general.  The mechanism of action utilizes an antibody with a solution which blocks ACE2 receptors found in nasal epithelial cells.  The nasal spray may possibly decrease the severity of clinical manifestations in infected patients by decreasing the initial Covid-19 viral load.

The technology covered in this provisional patent application is fully compatible with Halberd’s current research and extends it to address all three phases of the coronavirus:

  1. A Preventative and Early Treatment;
  2. A Diagnostic, and
  3. A Therapeutic Treatment.

Dr. Mitchell S. Felder, inventor of this treatment process, stated, “Multiple medical articles (1, 2) have shown that intranasal ACE2 receptors have been a key factor in the Covid-19 infectious process. Recent medical articles (3, 4) have shown the importance of the initial viral load in ultimately determining clinical manifestations.”

Mr. William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, “We continue to closely monitor technology advancements, across all of our sites, in the fight against Covid-19 and develop products to address the most pressing needs.  We continue to make progress towards this goal.”

For more information please contact:
William A. Hartman

About Halberd Corporation.
Halberd Corporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements.  Halberd’s Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company’s Articles of Incorporation here.  The number of outstanding shares remains at 317,721,539.

The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus”, and, “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans.”  Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.


Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.